ANTINEOPLASTIC AGENTS: CONCURRENT USE OF ANTINEOPLASTIC AGENTS AND AMPHOTERICIN-B MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION.
ANTINEOPLASTIC AGENTS SHOULD BE GIVEN CONCOMITANTLY WITH FUNGIZONE WITH GREAT CAUTION. CONCURRENT USE OF CORTICOSTEROIDS AND CORTICOTROPIN (ACTH) WITH AMPHOTERICIN B MAY POTENTIATE HYPOKALEMIA WHICH COULD
PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION, SERUM ELECTROLYTES AND CARDIAC FUNCTION SHOULD BE CLOSELY MONITORED.
CYCLOSPORIN-A CONCURRENT INITIATION OF CYCLOSPORIN A AND FUNGIZONE WITHIN SEVERAL DAYS OF BONE MARROW ABLATION MAY BE ASSOCIATED WITH INCREASED NEPHROTOXICITY. AMPHOTERICIN B MAY INDUCE HYPOKALEMIA
AND MAY POTENTIATE DIGITALIS TOXICITY. WHEN ADMINISTERED CONCOMITANTLY WITH DIGOXIN. CONCURRENT USE OF FLUCYTOSINE WITH AMPHOTERICIN B-CONTAINING PREPARATIONS MAY INCREASE THE TOXICITY OF FLUCYTOSINE BY POSSIBLY INCREASING ITS CELLULAR UPTAKE AND/OR IMPAIRING ITS RENAL EXCRETION. IMIDAZOLES (E.G., KETOCONAZOLE, MICONAZOLE, CLOTRIMAZOLE, FLUCONAZOLE, ETC):ANTAGONISM BETWEEN AMPHOTERICIN B AND IMIDAZOLE DERIVATIVES SUCH AS MICONAZOLE AND KETOCONAZOLE, WHICH INHIBIT ERGOSTEROL SYNTHESIS, HAS BEEN REPORTED IN BOTH
IN VITRO AND IN VIVO ANIMAL STUDIES. THE CLINICAL SIGNIFICANCE OF THESE FINDINGS HAS NOT BEEN DETERMINED. OTHER NEPHROTOXIC MEDICATIONS: CONCURRENT USE OF AMPHOTERICIN B AND AGENTS SUCH AS AMINOGLYCOSIDES AND PENTAMIDINE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY.SKELETAL MUSCLE RELAXANTS: AMPHOTERICIN B-INDUCED HYPOKALEMIA MAY ENHANCE THE CURARIFORM EFFECT OF SKELETAL MUSCLE RELAXANTS (E.G., TUBOCURARINE) DUE TO HYPOKALEMIA. WHEN ADMINISTERED CONCOMITANTLY WITH FUNGIZONE, SERUM POTASSIUM LEVELS SHOULD BE CLOSELY MONITORED. ZIDOVUDINE: INCREASED MYELOTOXICITY AND NEPHROTOXICITY WERE OBSERVED IN DOGS.